Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

European Heart Journal

1 April 2021
Organised by: Logo
ESC Journals HEART FAILURE Chronic Heart Failure

Abstract

AbstractAims 

Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on cardiovascular and non-cardiovascular causes of death.

Methods and results 

DAPA-CKD was an international, randomized, placebo-controlled trial with a median of 2.4 years of follow-up. Eligible participants were adult patients with CKD, defined as a urinary albumin-to-creatinine ratio (UACR) 200–5000 mg/g and an estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2. All-cause mortality was a key secondary endpoint. Cardiovascular and non-cardiovascular death was adjudicated by an independent clinical events committee. The DAPA-CKD trial randomized participants to dapagliflozin 10 mg/day (n = 2152) or placebo (n = 2152). The mean age was 62 years, 33% were women, the mean eGFR was 43.1 mL/min/1.73 m2, and the median UACR was 949 mg/g. During follow-up, 247 (5.7%) patients died, of whom 91 (36.8%) died due to cardiovascular causes, 102 (41.3%) due to non-cardiovascular causes, and in 54 (21.9%) patients, the cause of death was undetermined. The relative risk reduction for all-cause mortality with dapagliflozin (31%, hazard ratio [HR] [95% confidence interval (CI)] 0.69 [0.53, 0.88]; P = 0.003) was consistent across pre-specified subgroups. The effect on all-cause mortality was driven largely by a 46% relative risk reduction of non-cardiovascular death (HR [95% CI] 0.54 [0.36, 0.82]). Deaths due to infections and malignancies were the most frequently occurring causes of non-cardiovascular deaths and were reduced with dapagliflozin vs. placebo.

Conclusion 

In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.

Contributors

Hiddo J L Heerspink
Hiddo J L Heerspink

Author

University Medical Centre Groningen Groningen , Netherlands (The)

Peter Rossing
Peter Rossing

Author

Steno Diabetes Center, Copenhagen Herlev , Denmark

Author

C Luquez
C Luquez

Author

N Cluigt
N Cluigt

Author

M Mayer
M Mayer

Author

J Bittar
J Bittar

Author

N Garcia
N Garcia

Author

L Sivak
L Sivak

Author

L N Maia
L N Maia

Author

L Deboni
L Deboni

Author

H Bajaj
H Bajaj

Author

S S Chow
S S Chow

Author

G Bailey
G Bailey

Author

D Gaudet
D Gaudet

Author

F Madore
F Madore

Author

A Dowell
A Dowell

Author

A Levin
A Levin

Author

F Hou
F Hou

Author

Y Xue
Y Xue

Author

L Zuo
L Zuo

Author

C Hao
C Hao

Author

Z Ni
Z Ni

Author

C Xing
C Xing

Author

N Chen
N Chen

Author

Y Dong
Y Dong

Author

R Zhou
R Zhou

Author

X Xiao
X Xiao

Author

Y Zou
Y Zou

Author

C Wang
C Wang

Author

B Liu
B Liu

Author

Q Chen
Q Chen

Author

M Lin
M Lin

Author

Q Luo
Q Luo

Author

D Zhang
D Zhang

Author

J Wang
J Wang

Author

M Chen
M Chen

Author

X Wang
X Wang

Author

A Zhong
A Zhong

Author

J Dong
J Dong

Author

C Zhu
C Zhu

Author

T Yan
T Yan

Author

P Luo
P Luo

Author

Y Ren
Y Ren

Author

P Pai
P Pai

Author

D Li
D Li

Author

R Zhang
R Zhang

Author

J Zhang
J Zhang

Author

M Xu
M Xu

Author

Y Zhuang
Y Zhuang

Author

Y Kong
Y Kong

Author

X Yao
X Yao

Author

X Peng
X Peng

Author

R Borg
R Borg

Author

D Hansen
D Hansen

Author

M Hornum
M Hornum

Author

H Haller
H Haller

Author

T Kruger
T Kruger

Author

P Gross
P Gross

Author

C Hugo
C Hugo

Author

L Rose
L Rose

Author

J Muller
J Muller

Author

K Budde
K Budde

Author

P Voros
P Voros

Author

M Dudas
M Dudas

Author

A Letoha
A Letoha

Author

I Balku
I Balku

Author

G Zakar
G Zakar

Author

I Mezei
I Mezei

Author

G G Nagy
G G Nagy

Author

J Lippai
J Lippai

Author

A Nemeth
A Nemeth

Author

V A Rao
V A Rao

Author

D Dewan
D Dewan

Author

H Alva
H Alva

Author

Y Kadam
Y Kadam

Author

Y Abe
Y Abe

Author

T Imai
T Imai

Author

Y Onishi
Y Onishi

Author

Y Fujita
Y Fujita

Author

Y Tokita
Y Tokita

Author

Y Makita
Y Makita

Author

R Koyama
R Koyama

Author

Y Ando
Y Ando

Author

T Tanaka
T Tanaka

Author

S Hidaka
S Hidaka

Author

T Gohda
T Gohda

Author

K Tamura
K Tamura

Author

M Abe
M Abe

Author

Y Kamijo
Y Kamijo

Author

M Tomita
M Tomita

Author

F Hirano
F Hirano

Author

E Imai
E Imai

Author

M Waki
M Waki

Author

J Wada
J Wada

Author

K Uehara
K Uehara

Author

K Ota
K Ota

Author

K Tamura
K Tamura

Author

I Narita
I Narita

Author

M Iinuma
M Iinuma

Author

S Sasaki
S Sasaki

Author

S Kang
S Kang

Author

S Lee
S Lee

Author

C S Lim
C S Lim

Author

H Chin
H Chin

Author

K W Joo
K W Joo

Author

S Y Han
S Y Han

Author

S Park
S Park

Author

H Park
H Park

Author

C W Park
C W Park

Author

B G Han
B G Han

Author

D R Cha
D R Cha

Author

S A Yoon
S A Yoon

Author

W Kim
W Kim

Author

S W Kim
S W Kim

Author

D Ryu
D Ryu

Author

R Vargas
R Vargas

Author

A Dextre
A Dextre

Author

L Leon
L Leon

Author

G Molina
G Molina

Author

R Isidto
R Isidto

Author

R A Sy
R A Sy

Author

M E Lim
M E Lim

Author

H Rudzki
H Rudzki

Author

K Landa
K Landa

Author

M Golski
M Golski

Author

W Klatko
W Klatko

Author

S Mazur
S Mazur

Author

S Berns
S Berns

Author

R Nilk
R Nilk

Author

T Medina
T Medina

Author

A Rebrov
A Rebrov

Author

A Saeed
A Saeed

Author

K Dreja
K Dreja

Author

J Spaak
J Spaak

Author

V Stus
V Stus

Author

O Legun
O Legun

Author

I Dudar
I Dudar

Author

L Zub
L Zub

Author

P Mark
P Mark

Author

D Fraser
D Fraser

Author

P Kalra
P Kalra

Author

S P Kon
S P Kon

Author

S P Kon
S P Kon

Author

A Arif
A Arif

Author

G Bueso
G Bueso

Author

K W Carr
K W Carr

Author

N Daboul
N Daboul

Author

J Earl
J Earl

Author

R J Graf
R J Graf

Author

R Reddy
R Reddy

Author

R Trejo
R Trejo

Author

J K Wise
J K Wise

Author

A Wynne
A Wynne

Author

B V Khan
B V Khan

Author

A Jamal
A Jamal

Author

D Ross
D Ross

Author

A Tan
A Tan

Author

F Ovalle
F Ovalle

Author

J Talano
J Talano

Author

N Aslam
N Aslam

Author

S Goral
S Goral

Author

D Weiner
D Weiner

Author

M Yu
M Yu

Author

T Le
T Le

Author

T D
T D

Author

N Nguyen
N Nguyen

Author

H Nguyen
H Nguyen

Author

D Nguyen
D Nguyen

Author

V Nguyen
V Nguyen

Author

T Do
T Do

Author

P Chu
P Chu

Author

D Ta
D Ta

Author

N Tran
N Tran

Author

D Nguyen
D Nguyen

Author

ESC 365 is supported by